Pulmonary Drug Delivery Systems Market: Current Trends and Future Opportunities

The global Pulmonary Drug Delivery Systems Market size is expected to reach USD 55.1 billion by 2025, according to a new report by Grand View Research, Inc., Increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems (PDDS). As per WHO, 235 million people suffer from asthma globally. Majority of the asthma related deaths occur in middle- to low-income countries due to lack of treatment options. This shows the potential demand for pulmonary drug delivery systems in the coming years.

Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market. These advancements include incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.

Furthermore, rise in number of public and private organizations is another major factor propelling the growth of pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting overall market growth.

Browse Details of Report @
http://www.grandviewresearch.com/industry-analysis/pulmonary-drug-delivery-systems-market

Further Key Findings From the Study Suggest:

• Metered dose inhaler segment held the dominant share owing to its low cost and high adoption rate due to early introduction in the market
• Chronic Obstructive Pulmonary Diseases (COPD) segment is anticipated to grow at a lucrative CAGR due to the presence of favorable reimbursement policies for treatment of COPD
• High number of patients affected by asthma in developing and developed regions is likely to support the development of asthma applications for respiratory drug delivery devices
• E-commerce segment is expected to witness lucrative growth. Development of this segment is supported by its associated benefits such as convenience, discounts, and flexibility
• Home care segment is expected to exhibit exponential growth due to the introduction of technologically advanced, portable, and small-sized devices that can be used at home
• Asia Pacific region is anticipated to grow at a lucrative CAGR. High prevalence of COPD, indicating a substantial socioeconomic burden in this region drives the growth in Asia Pacific
• The pulmonary drug delivery systems market is progressing due to the rising demand for better treatment options, efficient drug delivery, and rapid treatment of local respiratory disorders

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com